Savara Inc. (SVRA)
Largest Insider Buys in Sector
SVRA Stock Price History Chart
SVRA Stock Performance
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Insider Activity of Savara Inc.
Over the last 12 months, insiders at Savara Inc. have bought $0 and sold $885,323 worth of Savara Inc. stock.
On average, over the past 5 years, insiders at Savara Inc. have bought $4.31M and sold $481,596 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 333,333 shares for transaction amount of $999,999 was made by Yang Rick (10 percent owner) on 2023‑07‑17.
List of Insider Buy and Sell Transactions, Savara Inc.
| 2023-12-28 | Sale | CHIEF EXECUTIVE OFFICER | 84,000 0.0609% | $4.71 | $395,900 | -6.76% | ||
| 2023-12-28 | Sale | CHIEF FINANCIAL OFFICER | 10,000 0.0072% | $4.71 | $47,131 | -6.76% | ||
| 2023-12-28 | Sale | director | 93,843 0.068% | $4.71 | $442,291 | -6.76% | ||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-07-17 | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.17% | |||
| 2023-06-26 | Chief Medical Officer | 6,500 0.0047% | $2.93 | $19,045 | +53.21% | |||
| 2023-05-26 | director | 37,124 0.024% | $2.63 | $97,599 | +44.36% | |||
| 2023-05-25 | director | 12,876 0.0084% | $2.57 | $33,130 | +48.84% | |||
| 2023-05-24 | director | 50,000 0.0322% | $2.56 | $127,800 | +47.69% | |||
| 2022-12-30 | director | 29,000 0.0189% | $1.55 | $44,834 | +101.94% | |||
| 2022-12-29 | director | 7,000 0.0046% | $1.54 | $10,752 | +104.58% | |||
| 2022-12-28 | director | 3,293 0.0021% | $1.50 | $4,923 | +107.67% |
Insider Historical Profitability
| Pauls Matthew | CHIEF EXECUTIVE OFFICER | 1302674 0.7914% | $3.81 | 10 | 1 | <0.0001% |
| Lowrance David L | CHIEF FINANCIAL OFFICER | 342355 0.208% | $3.81 | 3 | 11 | +23.24% |
| SANDELL SCOTT D | 10 percent owner | 24471264 14.867% | $3.81 | 1 | 0 | |
| BASKETT FOREST | 10 percent owner | 24471264 14.867% | $3.81 | 1 | 0 | |
| Mathers Edward T | 10 percent owner | 24471264 14.867% | $3.81 | 1 | 0 |
Institutional Investor Ownership
| Nea Management Company Llc | $121.87M | 14.88 | 24.47M | 0% | +$0 | 0.57 | |
| Bain Capital Life Sciences Investors Llc | $72.54M | 8.86 | 14.57M | +2.34% | +$1.66M | 5.84 | |
| Tcg Crossover Management Llc | $49.8M | 6.08 | 10M | 0% | +$0 | 0.08 | |
| JENNISON ASSOCIATES LLC | $44.03M | 5.38 | 8.84M | +0.3% | +$132,532.73 | 0.03 | |
| Adage Capital Partners Gp L L C | $41.27M | 5.04 | 8.29M | +8.51% | +$3.24M | 0.08 |